 |
 |
 |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | FDA Centennial
|
FOR IMMEDIATE RELEASE |
Media
Inquiries: |
The Food and Drug Administration (FDA) today announced the appointment of Mark Goldberger, MD, MPH, as Medical Director for Emerging and Pandemic Threat Preparedness in FDA's Center for Biologics Evaluation and Research (CBER). Dr. Goldberger was selected after a national search of eligible candidates. In this newly created position, Dr. Goldberger will serve as a Senior Advisor for CBER's pandemic flu program to plan, coordinate and implement activities related to the development and evaluation of products for emerging and pandemic threats.
"Emerging infectious diseases present a constant challenge for public health agencies, and FDA is committing resources and leadership to combat this growing threat. The creation of this position and Dr Goldberger's appointment together represent an important step forward in that effort." said Acting FDA Commissioner Andrew von Eschenbach, MD. "Dr. Goldberger has been at the forefront of combating other emerging infectious diseases, and we are grateful he has agreed once more to help tackle another monumental challenge, preparing for pandemic influenza and other future threats."
Dr. Goldberger began his career with the agency in 1989 as a medical reviewer, and currently serves as the Director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research (CDER). He received his medical degree from Columbia University where he also did his Medical Residency and Infectious Diseases Fellowship, and practiced and taught clinical Infectious Diseases for nearly 10 years. He also served as an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention (CDC), performing outbreak investigations and work on Swine Flu vaccine-associated Guillian-Barre syndrome.
"Dr. Goldberger's expertise and dedication to our public health mission will help enhance our preparedness activities," said Jesse L. Goodman, MD, MPH, Director of CBER. "His regulatory and public health experience with a wide range of infectious diseases and emerging threats, including influenza, SARS, pandemic influenza and West Nile Virus, will be a major asset in our strategic response."
Dr. Goldberger will be part of CBER's Senior Leadership Team, and will chair CBER's Pandemic Influenza Steering Committee (PISC). He will begin meeting with staff over the next few weeks and will be joining the Center full time at the end of August.
####
RSS Feed for FDA News Releases [what's this?]
Get
free weekly updates about FDA press releases, recalls, speeches, testimony
and more.